Financial News
All News about Incyte Corp
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2022/10/stocks-to-buy-greedy1600-1024x576.png)
![](https://mms.businesswire.com/media/20240310012701/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240310275231/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.png?width=1200&height=800&fit=crop)
The Analyst Verdict: Incyte In The Eyes Of 8 Experts
February 14, 2024
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2020/10/child-cancer-patient.jpg)
![](https://mms.businesswire.com/media/20240304329736/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240229692531/en/2050221/5/TUJ_VOMPN_Logo_Primary.jpg)
![](https://mms.businesswire.com/media/20240227083647/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://investorplace.com/wp-content/uploads/2019/07/biotech1600molecule.jpg)
![](https://mms.businesswire.com/media/20240215941438/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://mms.businesswire.com/media/20240213408157/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://cdn.benzinga.com/files/images/story/2024/Novartis_0.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2018/04/STOCK-Novartis-02-shutter.jpg)
![](https://mms.businesswire.com/media/20240205431773/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
February 05, 2024
From Incyte
Via Business Wire
![](https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715.png)
![](https://cdn.benzinga.com/files/images/story/2024/people-95715-1280.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://www.marketbeat.com/logos/articles/med_20240124120518_5-top-healthcare-stocks-for-earnings-growth-in-202.jpg)
![](https://mms.businesswire.com/media/20240123747153/en/1078784/22/Incyte_Color_Logo_JPEG_2colorpos.jpg)
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
January 23, 2024
From Incyte
Via Business Wire
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600.png)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.